Our Science

We want to help people living with debilitating conditions by developing non-addictive pain medications to reduce reliance on opioids.

The Endocannabinoid System (ECS), a key biological system in the human body, plays an important role in maintaining balance in physiological functions, including pain regulation, inflammation, and immune response.

At Octavian, our goal aligns with doctors and regulators who seek scientific validation of how targeting the ECS can restore physiological balance when disrupted by disease.

We are focused on three categories of compounds in our drug development pipeline: New Chemical Entities (NCEs) – fully synthetic molecules designed to interact with the ECS; in-licensed compounds – selected from leading pharmaceutical sources to accelerate development; and Octavian proprietary compounds – derivatives designed to optimise drug-like characteristics and expand treatment possibilities.